Doctor profile · Federal record
Dr. Scott Stoerner, MD
Rheumatology Physician (CMS: Rheumatology) · Albuquerque, NM
- NPI 1053507715
- Accepts Medicare
- MIPS 96.5 / 100 · 2023
- 21 yrs in practice
- Male
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
4901 Lang Ave Ne
Albuquerque, NM 871094397
(505) 842-8171
fax (505) 246-0684
Credentials & registration
- NPI registered
- September 2007 — 19 yrs on file
- Profile last updated
- March 4, 2025
- Year of graduation
- 2005 — 21 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- New Mexico #MD2010-0288
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1053507715. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
128,760
Distinct HCPCS
10
Medicare allowed
$1,894,883
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 66,401 | 25 | $5 | |
J3262 |
Injection, tocilizumab, 1 mg | 19,800 | 11 | $6 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 16,081 | 22 | $13 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14,150 | 29 | $42 | |
J9312 |
Injection, rituximab, 10 mg | 4,150 | 15 | $80 | |
J0897 |
Injection, denosumab, 1 mg | 2,100 | 24 | $23 | |
Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2,040 | 14 | $37 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 1,710 | 14 | $33 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 397 | 218 | $120 | |
96372 |
Injection of drug or substance under skin or into muscle | 389 | 43 | $13 |
In context: peer comparison
Among 12 peers in this city , average services per provider: 2,027. This provider delivers 64× the peer median.Open Payments
Industry payments received
All-time total
$558
Transactions
34
Manufacturers
9
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 22 | $306.94 | |
| AstraZeneca Pharmaceuticals LP | 5 | $88.42 | |
| SOBI, INC | 1 | $37.48 | |
| GlaxoSmithKline, LLC. | 1 | $27.80 | |
| UCB, Inc. | 1 | $24.24 | |
| Novartis Pharmaceuticals Corporation | 1 | $22.10 | |
| Amgen Inc. | 1 | $19.65 | |
| GENZYME CORPORATION | 1 | $18.35 | |
| Teva Pharmaceuticals USA, Inc. | 1 | $13.45 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
2,153
Patients
518
Total drug cost
$1,071,849
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate | Generic | 524 | 128 | $35,029 |
| Methotrexate (Methotrexate Sodium) | Brand | 495 | 107 | $23,303 |
| Prednisone | Generic | 362 | 124 | $3,315 |
| Allopurinol | Generic | 103 | 33 | $2,221 |
| Alendronate Sodium | Generic | 90 | 21 | $1,143 |
| Baclofen | Generic | 74 | 16 | $1,720 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 74 | 28 | $2,511 |
| Leflunomide | Generic | 71 | 22 | $6,733 |
| Enbrel Sureclick (Etanercept) | Brand | 65 | 0 | $510,463 |
| Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) | Brand | 64 | 0 | $337 |
Frequently asked questions
What is Dr. Scott Stoerner's medical specialty?
Dr. Scott Stoerner practices Rheumatology Physician in Albuquerque, NM.
Where does Dr. Scott Stoerner practice?
Dr. Scott Stoerner practices at 4901 Lang Ave Ne, Albuquerque, NM 871094397. Office phone: 5058428171.
What is Dr. Scott Stoerner's NPI?
Dr. Scott Stoerner's National Provider Identifier (NPI) is 1053507715, issued by NPPES.
Does Dr. Scott Stoerner accept Medicare assignment?
Yes. Dr. Scott Stoerner accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Scott Stoerner commonly perform?
Top Medicare-reported procedures in 2023: Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717); Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602). Source: CMS Medicare Physician & Other Practitioners file.